My own best guess is that Eli Lilly, Amylin, and Boehringer will work out their differences in a manner that will allow them to continue doing business in something akin to their marketing arrangements now in place.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing